Periodic Reporting for period 1 - isitFlutter (dIagnoSIs app for regular aTrial arrhytmia like Flutter)
Reporting period: 2016-10-01 to 2018-03-31
We have been developing a new diagnosis tool for cardiac arrhythmia for expert cardiologists. They can use our Demonstrator App with a Smartphone or Tablet, easily and cost-efficiently. The App records the beeps of a heart rate monitor or takes a picture of the printout of an electrocardiogram (ECG), communicates with a server, and displays the result of the calculations as decision support for the medical expert.
Depending on the diagnosis of the medical expert either a long-term treatment with drugs or an operation follows. The correct diagnosis and proper treatment implies an increased life quality and a reduction of unnecessary drug side effects (for patients); avoidance of legal disputes and higher success rates (for doctors); reduced costs (for health insurance companies); and an increase in the number of profitable procedures (for providers of ablation technology). Alas, the misdiagnosis rate of expert cardiologists and of competing diagnosis tools so far is high. Studies report success rates of 50%. We showed in a peer-reviewed study that our success rate is almost 90%.
As an outcome of the isitFlutter project a Demonstrator App was developed that allows cardiologists in hospitals to use it in their daily work and that allows health insurance companies or ECG manufacturers to consider an investment into the underlying technology. The diagnosis is a daily task for cardiologists in Europe, with an estimated number of one million diagnoses per year. We extended the clinical testing into the direction of possible dissemination and adapted our product accordingly, evaluated competition and IPR, and extended our contacts with future customers, investors, and players in the market.
Depending on the diagnosis of the medical expert either a long-term treatment with drugs or an operation follows. The correct diagnosis and proper treatment implies an increased life quality and a reduction of unnecessary drug side effects (for patients); avoidance of legal disputes and higher success rates (for doctors); reduced costs (for health insurance companies); and an increase in the number of profitable procedures (for providers of ablation technology). Alas, the misdiagnosis rate of expert cardiologists and of competing diagnosis tools so far is high. Studies report success rates of 50%. We showed in a peer-reviewed study that our success rate is almost 90%.
As an outcome of the isitFlutter project a Demonstrator App was developed that allows cardiologists in hospitals to use it in their daily work and that allows health insurance companies or ECG manufacturers to consider an investment into the underlying technology. The diagnosis is a daily task for cardiologists in Europe, with an estimated number of one million diagnoses per year. We extended the clinical testing into the direction of possible dissemination and adapted our product accordingly, evaluated competition and IPR, and extended our contacts with future customers, investors, and players in the market.